🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are increasing around the world, with figures suggesting more than 82 million new cases each year. Especially elevated rates are seen in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the face of rising global incidence, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for use against gonorrhoea. This disease can lead to major issues, including infertility. Researchers hope that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in concurrent days. This medication, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This milestone represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

According to results detailed in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This places it at an similar efficacy with the typical regimen, which involves two antibiotics. The study involved over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in many developing nations.

Medical professionals directly involved have expressed positive views. Access to a one-pill regimen of this kind is hailed as a "game-changer" for public health efforts. This is viewed as vital to lessen the impact of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.